Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02681991|
Recruitment Status : Completed
First Posted : February 15, 2016
Last Update Posted : July 6, 2017
Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic renal failure.
120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl).
Renamezin is administered 6.0mg/day. The treatment period is 2 months. The change in serum indoxyl sulfate will be evaluated.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Renal Failure||Drug: Renamezin capsule||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||110 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2016|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||September 2016|
Renamezin capsule 2g, tid, PO
Drug: Renamezin capsule
- change from baseline of Indoxyl sulfate at 8weeks [ Time Frame: 0, 8weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02681991
|Korea, Republic of|
|Gangnam Sevrance Hospital of Yonsei University|
|Seoul, Gangnam-gu, Korea, Republic of, 06273|
|Principal Investigator:||Hyeong-Cheon Park, Professor||Gangnam Sevrance Hospital of Yonsei University|